Dr. Lindsley’s research focuses on the biology and treatment of myeloid malignancies, with specific emphases on familial leukemia predisposition and understanding donor and recipient factors that drive clinical outcomes after bone marrow transplantation. His work has been incorporated into revisions of the World Health Organization (WHO) and International Consensus Classifications (ICC) of leukemia and new models for understanding MDS outcome after transplantation.

Dr. Lindsley is an Associate Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, where he is Director of the Edward P. Evans Center for Myelodysplastic Syndrome and Director of Clinical Genomics in Hematologic Malignancies. He is and a laboratory investigator in the Division of Hematologic Neoplasia at DFCI and an Associate Member of the Broad Institute of Harvard and MIT.

He received a bachelor’s degree in Music from Swarthmore College and an M.D. and Ph.D. in Immunology from Washington University School of Medicine. He completed a residency in internal medicine at Brigham and Women’s Hospital and a fellowship in oncology at the Dana-Farber Cancer Institute.